199 related articles for article (PubMed ID: 30148651)
1. Anticoagulation at the extremes of body weight: choices and dosing.
McCaughan GJB; Favaloro EJ; Pasalic L; Curnow J
Expert Rev Hematol; 2018 Oct; 11(10):817-828. PubMed ID: 30148651
[TBL] [Abstract][Full Text] [Related]
2. Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations.
van Es N; Büller HR
Hematology Am Soc Hematol Educ Program; 2015; 2015():125-31. PubMed ID: 26637711
[TBL] [Abstract][Full Text] [Related]
3. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
4. Laboratory testing in the era of direct or non-vitamin K antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errors.
Favaloro EJ; Lippi G
Semin Thromb Hemost; 2015 Mar; 41(2):208-27. PubMed ID: 25703514
[TBL] [Abstract][Full Text] [Related]
5. Use of the Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism.
Riva N; Ageno W
Hematol Oncol Clin North Am; 2016 Oct; 30(5):1035-51. PubMed ID: 27637306
[TBL] [Abstract][Full Text] [Related]
6. Current challenges and future prospects in oral anticoagulant therapy.
Czuprynska J; Patel JP; Arya R
Br J Haematol; 2017 Sep; 178(6):838-851. PubMed ID: 28573648
[TBL] [Abstract][Full Text] [Related]
7. Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges.
Chen A; Stecker E; A Warden B
J Am Heart Assoc; 2020 Jul; 9(13):e017559. PubMed ID: 32538234
[TBL] [Abstract][Full Text] [Related]
8. The evolution of anticoagulant therapy.
Franchini M; Liumbruno GM; Bonfanti C; Lippi G
Blood Transfus; 2016 Mar; 14(2):175-84. PubMed ID: 26710352
[TBL] [Abstract][Full Text] [Related]
9. New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs).
van Gorp RH; Schurgers LJ
Nutrients; 2015 Nov; 7(11):9538-57. PubMed ID: 26593943
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban in the treatment of venous thromboembolism and the prevention of recurrences: a practical approach.
Arcelus JI; Domènech P; Fernández-Capitan Mdel C; Guijarro R; Jiménez D; Jiménez S; Lozano FS; Monreal M; Nieto JA; Páramo JA
Clin Appl Thromb Hemost; 2015 May; 21(4):297-308. PubMed ID: 25504999
[TBL] [Abstract][Full Text] [Related]
11. Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents.
Sciascia S; Radin M; Schreiber K; Fenoglio R; Baldovino S; Roccatello D
Intern Emerg Med; 2017 Dec; 12(8):1101-1108. PubMed ID: 28929298
[TBL] [Abstract][Full Text] [Related]
12. Direct oral anticoagulants in the treatment of pulmonary embolism.
Eldredge JB; Spyropoulos AC
Curr Med Res Opin; 2018 Jan; 34(1):131-140. PubMed ID: 28771049
[TBL] [Abstract][Full Text] [Related]
13. Factor Xa and thrombin as targets for new oral anticoagulants.
Weitz JI
Thromb Res; 2011 Jan; 127 Suppl 2():S5-S12. PubMed ID: 21193114
[TBL] [Abstract][Full Text] [Related]
14. [Vitamin K antagonist, direct oral anticoagulants: Where is the truth?].
Laroche JP; Schved JF
J Mal Vasc; 2016 Dec; 41(6):383-388. PubMed ID: 27817997
[TBL] [Abstract][Full Text] [Related]
15. Pros and cons of new oral anticoagulants.
Bauer KA
Hematology Am Soc Hematol Educ Program; 2013; 2013():464-70. PubMed ID: 24319220
[TBL] [Abstract][Full Text] [Related]
16. Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
Gibson CM; Finks SW
Am J Med; 2017 Aug; 130(8):900-906. PubMed ID: 28390791
[TBL] [Abstract][Full Text] [Related]
17. Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation.
McCarty D; Robinson A
Ther Adv Cardiovasc Dis; 2016 Feb; 10(1):37-49. PubMed ID: 26378211
[TBL] [Abstract][Full Text] [Related]
18. Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: a meta-analysis of randomized controlled trials.
Di Minno MN; Lupoli R; Di Minno A; Ambrosino P; Scalera A; Dentali F
Ann Med; 2015 Feb; 47(1):61-8. PubMed ID: 25665582
[TBL] [Abstract][Full Text] [Related]
19. Preference for direct oral anticoagulants in patients treated with vitamin K antagonists for venous thromboembolism.
Brekelmans MP; Kappelhof M; Nieuwkerk PT; Nierman M; Buller HR; Coppens M
Neth J Med; 2017 Mar; 75(2):50-55. PubMed ID: 28276323
[TBL] [Abstract][Full Text] [Related]
20. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
Marik PE; Cavallazzi R
PLoS One; 2015; 10(11):e0143252. PubMed ID: 26587983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
